Loading organizations...
§ Private Profile · Södertälje, Vasternorrlands Lan, Sweden
Biotechnology company developing TCR-T therapies for solid tumors, infectious, and autoimmune diseases via proprietary T-cell biology platform.
Based in Södertälje, Sweden, Anocca is a biopharmaceutical company that develops and manufactures T cell receptor-engineered T cell (TCR-T) therapies for solid tumors, infectious diseases, and autoimmune conditions. The organization utilizes proprietary technology platforms to analyze human T-cell biology at scale, enabling the discovery and engineering of novel targeted immunotherapies. Operating the largest cell-therapy manufacturing facility in the Nordic region, the enterprise employs approximately 120 people to advance its pre-clinical and clinical pipeline. To support ongoing research and manufacturing expansion, Anocca has secured licensing agreements with partners like EmendoBio. The firm has raised approximately €100 million in total funding, including €25 million in venture debt from the European Investment Bank and equity investments from Swedbank Robur, AMF, and Mellby Gård. The biotechnology company was founded in 2014 by Reagan Jarvis and Mikael Blomqvist.
Anocca has raised $109.3M across 3 funding rounds.
Anocca has raised $109.3M in total across 3 funding rounds.
Anocca has raised $109.3M in total across 3 funding rounds.
Anocca's investors include Johan Andersson, AMF, Stefan Persson, Anders Oscarsson, Mellby G ard, Michano, Nidoco, Ramsbury Invest, Swedbank Robur, Paolo Gentiloni.
Anocca has raised $109.3M across 3 funding rounds. Most recently, it raised $46.1M Other Equity in August 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 18, 2025 | $46.1M Venture Round | Johan Andersson | AMF, Stefan Persson | Announced |
| May 31, 2023 | $36.7M Venture Round | Anders Oscarsson, Mellby G ARD | Michano, Nidoco, Ramsbury Invest, Swedbank Robur | Announced |
| Dec 21, 2022 | $26.6M Debt Financing | Paolo Gentiloni | — | Announced |